Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I was not happy to see .75 print today. May the 2.00 prophecy be our gap up pps in the near future...
16,000 shares here...
GLTA.
The management on this company is astonished by the current valuation. In their interpretation of the recent news shares of BVTI should be trading north of $2 a shares. The damage associated with the sale of shares by creditors wasn't anticipated but, as most biotech companies know they have little to do with the streets interpretation of value. As news unfolds over the next few months shares should respond positively.
Will anyone be watching this? If yo are can I get an honest report from you?
Doctors have known for some time that people’s immune systems may help fight their cancer. In rare instances, these people’s immune systems have rejected their cancers, and they have been cured. Scientists are now trying to develop ways to encourage this immune reaction by the use of vaccines.
Unlike vaccines against infections like measles or mumps, these vaccines are designed to help treat, not prevent, lymphomas. The goal is to create an immune reaction against lymphoma cells in patients who have very early disease or in patients whose disease is in remission. One possible advantage of these types of treatments is that they seem to have very limited side effects. So far, there have been a few successes with this approach, and it is a major area of research in lymphoma treatment. At this time lymphoma vaccines are only available in clinical trials.
BiovaxID™ is a vaccine based on the unique genetic makeup of a patient’s B-cell non-Hodgkin lymphoma. The vaccine uses a unique protein (part of an antibody called an idiotype) taken from each patient’s own lymphoma cells, which are obtained during a biopsy. This is combined with substances that boost the body’s immune response when the combination is injected into the patient. A late-stage clinical trial found that in people with follicular lymphomas that went away after chemotherapy, the vaccine lengthened the time before the lymphoma came back by more than a year. The vaccine is not yet available outside of clinical trials.
Someone just posted on another board that the short interest is very low and he believes that even shortie has BVTI undervalued. Can this be confirmed? If shortie does think BVTI is undervalued, will this lead the way to less resistance if the price starts to appreciate?
I rest my case! There is news this morning that further clarify s the Phase III trail results! This stock close the year above $1. YOW!!
Creditors are done selling shares of BVTI !
Share climb back above $1 before year end. Short squeeze helps push the shares back to $1.40 in January 2011.
$0.88 on comparatively low volume. Seems the creditors will sell no matter the price.
Damn the bleeding here just wont stop!! Sam Duffey and friends should have been more protective of the creditors dumping shares of BVTI on the heels of such great news!! I bought more today at $1 and will set a few limit orders at .90 and .80 just in case. This stock runs back above $2 a share once the creditors are done selling their shares!!
no telling how low it could go, but it bounced nicely yesterday from this level.
I've added at $1.09
How much lower can this go?
Anyone have any info when the FDA has the fast track date?
This all sure looks favorable to me. I have established a position and look forward to further positive developments.
Biovest’s President, Mr. Samuel S. Duffey, stated, “It is our sincere hope that this new data and its impact on future cancer vaccine development will be important to patients suffering from lymphoma. There is no other cancer vaccine that we are aware of, either approved or in clinical trials, that has conducted an isotype/idiotype analysis such as that reported today for BiovaxID. We believe that this new data may have potentially paradigm-changing implications to the future of cancer vaccine development and accordingly, we have filed new patent applications in order to add another layer of protection for BiovaxID, as well as potentially covering other new vaccines and products that may be developed based on this technology.”
Creditors have been selling shares since Biovest announced that they would be resolving their Bankruptcy issues. This recent pull back is a buying opportunity. Aren't they presenting at a conference next week in Orlando Fl? I believe that I read somewhere that BVTI is presenting Monday at a Hematology conference next week. I agree with your comment about shares of BVTI climbing back to $2 very quickly....GLTA
The only thing That I can come up with is it came out of bK and is an OTC. BUT I still don't understand how this company can have the fast track withe the FDA and still not much interest. Monday will be very telling.
i claim to have no knowledge of trading...
I've been keeping an eye on BVTI for a couple of months now. Personally, I think this is a good buying opportunity. What I don't understand is why the stock took such a hit when they emerged from bankruptcy. Was there some stock dilution going on? What's to stop BVTI from climbing back to $2.00+?
Why not is this company and product under the radar> I have no idea!
It has the fast track with the FDA and orphan drug status..
http://ash.confex.com/ash/2010/webprogram/Paper34600.html
such a great potential with this company and product. Great article in teh previous thread.
I just bought 100 shares of this company.
I just bought 100 shares of this company.
Is anyone else interested in this stock along with ABPIQ? something has been erking me about this company's cancer stuff. that these two companies will be big time.
BVTI 8k out, looks like good things coming!
Ballots posted for voting.
http://www.srbp.com/accentia/accentia.htm
return required by Sept 17th, Confirmation hearing Sept 22nd 1:00pm EST
Biovest Bioreactor System
http://finance.yahoo.com/news/Naval-Health-Research-Center-bw-69990411.html?x=0&.v=1
the good news just keeps coming
09/22/2010 next court date
@04:00PM 08-17795-8M1 ACCENTIA BIOPHARMACEUTICALS, INC., ET AL
Atty:CHARLES A. POSTLER
Trustee:UNITED STATES TRUSTEE - TPA, 1
1 - CONFIRMATION
2 - FOURTH APPLICATION FOR COMPENSATION FOR SALAWANCHICK, LLOYD AND SALAWANCHICK, SPECIAL COUNSEL, DOC. #840, FOR THE PERIOD 6/1/10 THROUGH 7/31/10 ($14,117.41/$10,973.13)
pulled from netdoc's
TAMPA, Fla. & MINNEAPOLIS, Aug 05, 2010 (BUSINESS WIRE) -- Biovest
International, Inc. (OTCQB: "BVTI"), a biotechnology company advancing its personalized cancer vaccine targeting non-Hodgkin's lymphoma, today announced that the Company has retained the investment banking firm, ROTH Capital Partners, LLC (ROTH). ROTH has been engaged to assist Biovest in raising capital
as the Company prepares to emerge from Chapter 11 reorganization.
I could never get a read on where ABPIQ and BVTI should be trading if/when fda actually accepts their NDA. I don't have my charts on this laptop but seems one of them had atleast a 3-4 dollar range. ABPIQ I think? I find it interesting the stock prices are now closing in to each other.. which is telling me something about ABPIQ yes? I'm gonna go out on a leash and say ABPIQ will be the drug of choice for the momentum players when the time comes.
Good article on Accentia/BioVest
http://www.biopharmaceuticalnews.blogspot.com/
Roth Capital & 09/30 Extension
another delay, gee another suprise extension
Biovest International product gets orphan drug status from FDA
http://www.bizjournals.com/stlouis/othercities/tampabay/stories/2010/07/26/daily2.html
Adam Feuerstein at it again and thestreet.com. As we have known and seen this A.F. has an agenda, to flop the stock. I prefer the the writings of James Hill MD, @ gene.md a share holder with an extreme education.
I'm long and still holding since my accumlation.
http://gene.md/2010/05/20/biovest-meets-... Due Dilegence is the name of the game
From thestreet.com and comments by chance56
" http://www.thestreet.com/storycomments/10813622/1/biotech-stock-mailbag-ziopharm.html
Please visit Dr. James Hill's explanation of why the 3 month production time is not the partnership hindrance that Adam has portrayed it to be...
http://seekingalpha.com/article/206258-biovest-meets-skeptic-s-requirements-for-the-next-dendreon-part-1
This is one in a four part series that specifically addresses many of the misrepresentations of BiovaxID's potential. All four parts can be viewed on Seeking Alpha or http://gene.md/
There is a great deal of misunderstanding in regards to BiovaxID's data and the financial status of both Biovest and Accentia. Read Hill's articles, read though the court docs (settlement agreement with Laurus, plans of reorganization and disclosure statements), look at existing blood cancer treatments and also FDA regulatory precendents before taking full acceptance of Adam's opinion on this one.
By chance56 on 7/22/10 12:49 PM"
Disclosure Statements its gonna pop......
DS for emergence,
http://www.srbp.com/accentia/accentia.htm
http://www.srbp.com/biovest/biovest.htm
from Yahoo board by mc_m98
Bankruptcy fails to derail biotech opportunists Accentia, Biovest
Read more: Bankruptcy fails to derail biotech opportunists Accentia, Biovest - Tampa Bay Business Journal
http://tampabay.bizjournals.com/tampabay/stories/2010/07/19/story6.html
"New Cancer Vaccine Kills Lymphoma, Now in Phase III Clinical Trials"
July 17th, 2010 by Drew Halley
http://singularityhub.com/2010/07/17/new...
From the Accentia Yahoo mb:
I agree, I think we will test 1.20 again before Aug 9th date. MM's are really squezzing the faint of heart. The old portfolio looked really good when we were pushing 2.00. now it looks rather depressing. Long in at .55 so I have ways to go before I run.
Biovest's Stock Listing Upgraded to OTCQB(TM) Market
http://www.foxbusiness.com/story/markets/industries/health-care/biovests-stock-listing-upgraded-otcqbtm-market/
Order Scheduling Hearing on Disclosure Statement
Hearing scheduled for 8/9/2010 at 01:30 PM at Tampa, FL
emergence is in view
Extention till Aug for lagard creditors.
looking for emergence July 2010
Disclosure Statement - Joint Disclosure Statement for Joint Plan of Reorganization of Biovest International, Inc., Biovax, Inc., AutovaxID, Inc.,
Biolender, LLC, and Biolender II, LLC under Chapter 11 of Title 11, United
States Code Filed by Charles A. Postler on behalf of Debtors AutovaxID, Inc.,
Biolender II, Inc., Biolender, LLC, Biovax, Inc., Biovest International, Inc..
(Postler, Charles) (Entered: 07/02/2010)
in preparation for emergence from BK.
available @ netdocs or thru Accentia Biopharmaceuticals Forum on Yahoo.
I am long on both companies, and I believe them both to be headed in the right direction. Hopefully this is simply profit being taken off the table while offering others a great entry point into 2 stocks that could take off within the next few months.
It seems to have the stench of a bear raid...
What is going on today with Accentia and Biovest????? I can't find any news to save my life that would justify this ridiculous drop. Anyone know anything?
Not sure; at least they were at one time. The news links they reference are old. However, BVTI's senior creditor is Laurus, with whom they just agreed to new terms and this was part of the reorg plan filed with the bankruptcy court recently.
Accentia and Biovest should emerge from bankruptcy soon. Hopefully, they will have a run like Dendreon.
Followers
|
17
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
320
|
Created
|
01/27/06
|
Type
|
Free
|
Moderators |
http://www.biovest.com
Biovest International Inc, is a majority-owned subsidiary of Accentia Biopharmaceuticals Inc., a vertically-integrated specialty biopharmaceutical company with services to commercialize targeted therapeutics. Accentia is a publicly traded company (NASDAQ: ABPI) that has a product portfolio featuring targeted therapeutics, specialty sales and marketing, pharmacoeconomic services, product development, and specialty distribution.
Biovest has a deep foundation in the manufacture of biological drugs from small research scale quantities to large volumes for Phase I and Phase II clinical material. In addition, Biovest International develops, manufactures, and markets patented cell culture systems and equipment to pharmaceutical, diagnostic and biotechnology companies, as well as leading research institutions worldwide. For over 10 years the company has operated the National Cell Culture Center (NCCC) under a grant from the National Institutes of Health.
Biovest is the holder of a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute for the commercialization of BiovaxID, a personalized biologic therapeutic cancer vaccine for the treatment of non-Hodgkin's lymphoma. This therapy, referred to as BiovaxID, is currently in a phase 3 pivotal trial at 24 major medical institutions in the US.
SEC FILINGS
http://phx.corporate-ir.net/phoenix.zhtml?c=154286&p=irol-sec
RECENT NEWS
http://finance.yahoo.com/q?s=BVTI.OB
DAILY CHART
WEEKLY CHART
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |